Young Hee Yoon
Asan Medical Center
OphthalmologyInternal medicineEndocrinologySurgeryRetrospective cohort studyRetinaVisual acuityRetinopathyOptical coherence tomographyDiabetic retinopathyFluorescein angiographyMacular edemaRetinal detachmentRetinalIntraocular pressureVitrectomyIn patientDiabetes mellitusMedicineBiology
209Publications
32H-index
4,091Citations
Publications 217
Newest
#1Arshad M. Khanani (University of Nevada, Reno School of Medicine)H-Index: 12
#2Robyn H. Guymer (University of Melbourne)H-Index: 73
Last. Balakumar Swaminathan (Hoffmann-La Roche)H-Index: 1
view all 13 authors...
Abstract null null Objective null To describe the design and rationale of phase 3 TENAYA (NCT03823287) and LUCERNE (NCT03823300) trials that aim to assess efficacy, safety, and durability of faricimab, the first bispecific antibody for intraocular use, which independently binds and neutralizes both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) versus aflibercept in patients with neovascular age-related macular degeneration (nAMD). null null null Design null Identical, ...
Source
#5Joo Yong Lee (UOU: University of Ulsan)H-Index: 35
Purpose. Retinitis pigmentosa (RP) shows great diversity between genotypes and phenotypes, and it is important to identify the causative genes. This study aimed to analyze the molecular profiles, associated ocular characteristics, and progression of RP in Korean patients. Methods. All the genetic variants in patients with RP, identified using targeted next-generation sequencing (NGS) with a panel of 88 RP-related genes between November 2018 and November 2019, were retrospectively reviewed. All t...
Source
#1Neil M. Bressler (Johns Hopkins University)H-Index: 50
#2Miroslav Veith (Charles University in Prague)H-Index: 3
Last. Se Joon Woo (New Generation University College)H-Index: 41
view all 19 authors...
Background/Aims null To provide longer-term data on efficacy, safety, immunogenicity and pharmacokinetics (PK) of ranibizumab biosimilar SB11 compared with the reference ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD). null Methods null Setting: Multicentre. Design: Randomised, double-masked, parallel-group, phase III equivalence study. Patient population: ≥50 years old participants with nAMD (n=705), one ‘study eye’. Intervention: 1:1 randomisation to mont...
Source
Source
#1Rahul N. KhuranaH-Index: 19
#2Derek Y KunimotoH-Index: 12
Last. Andrew J. Lotery (University of Southampton)H-Index: 68
view all 21 authors...
PURPOSE To report the 2-year efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) compared with monthly ranibizumab in patients with treatment-naive neovascular age-related macular degeneration (nAMD). DESIGN Two multicenter, randomized, phase 3 clinical trials with identical protocols (CEDAR and SEQUOIA). Analyses used pooled trial data. PARTICIPANTS The trials enrolled 1888 patients (1 eye/patient) with active choroidal neovascularization secondary to age-related m...
Source
#3Ko Eun Kim (Ajou University)H-Index: 14
Purpose To investigate the long-term progression of pericentral hydroxychloroquine retinopathy. Design Multicenter, retrospective cohort study. Participants Eighty eyes (60 with pericentral pattern) of 41 Korean patients with hydroxychloroquine retinopathy followed up for 2 years or more after drug cessation. Methods Patients were screened for hydroxychloroquine retinopathy using spectral-domain or swept-source OCT, fundus autofluorescence (FAF), and Humphrey visual field (VF) tests. Follow-up w...
Source
#1You Na Kim (UOU: University of Ulsan)H-Index: 1
#2Joong Won Shin (UOU: University of Ulsan)
Last. Yoon Jeon Kim (UOU: University of Ulsan)H-Index: 14
view all 7 authors...
PURPOSE To compare the functional and anatomical outcomes of central retinal vein occlusion (CRVO) according to the presence of glaucoma before the onset of CRVO, and to assess whether pre-existing glaucoma affects the prognosis of CRVO in terms of development and conversion to ischaemic CRVO. METHODS In this retrospective cohort study, patients with treatment-naive CRVO were enrolled between December 2009 and February 2019. The patients were classified into two groups according to the presence ...
Source
#1Kyu Sang Eah (UOU: University of Ulsan)H-Index: 1
#2You Na KimH-Index: 1
Last. Yoon Jeon KimH-Index: 14
view all 7 authors...
PURPOSE To investigate the clinical characteristics and prognostic factors of young patients with central retinal vein occlusion (CRVO). METHODS This retrospective cohort study involved treatment-naive patients with CRVO. Medical records regarding basic demographics, predisposing factors, ocular characteristics, and treatments were reviewed and compared according to age at CRVO onset. RESULTS We enrolled 263 patients, of whom 69 were younger patients. Younger patients had higher prevalence of no...
Source
#1Young Hee YoonH-Index: 32
#2Mark S. HumayunH-Index: 87
Last. Yoon Jeon KimH-Index: 14
view all 3 authors...
Purpose To report the anatomical and functional outcomes of Argus II retinal prosthesis implantation in Korean patients Methods:We included five consecutive patients with end-stage retinitis pigmentosa (RP) who underwent Argus II retinal prosthesis implantation and followed for at least 12 months. The transcorneal electrical evoked response was utilized for patient selection. We used intraoperative optical coherence tomography (OCT) for optimal placement of the array and provided specialized vis...
Source
#1Se Joon Woo (Seoul National University Bundang Hospital)H-Index: 41
#2Miroslav Veith (Charles University in Prague)H-Index: 3
Last. Neil M. Bressler (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 92
view all 16 authors...
Importance Neovascular age-related macular degeneration is the leading cause of blindness in individuals 50 years or older. The availability of a ranibizumab biosimilar product (SB11) may facilitate access to an effective alternative to this treatment. Objective To demonstrate equivalence of efficacy, similar safety, and similar immunogenicity of SB11 compared with the reference ranibizumab. Design, setting, and participants This randomized, double-masked, parallel-group phase 3 equivalence stud...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.